Technical Analysis for ALLK - Allakos Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.19 | -0.42% | -0.01 |
ALLK closed down 0.42 percent on Wednesday, May 15, 2024, on 57 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average.
Earnings due: May 24
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Fell Below 50 DMA | Bearish | -0.42% | |
| Crossed Above 50 DMA | Bullish | -2.87% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.87% | |
| Weak + Overbought | Other | -2.87% | |
| Wide Bands | Range Expansion | -2.87% | |
| Gapped Up | Strength | -2.87% | |
| Overbought Stochastic | Strength | -2.87% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| 50 DMA Resistance | about 18 hours ago |
| 10 DMA Resistance | about 18 hours ago |
| Down 1% | about 18 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/24/2024
Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Disease Immunology Immune System Antibodies Inflammation Antibody Cell Biology Allergy Allergic Conjunctivitis Mastocytosis Systemic Mastocytosis Mast Cell Eosinophil
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Disease Immunology Immune System Antibodies Inflammation Antibody Cell Biology Allergy Allergic Conjunctivitis Mastocytosis Systemic Mastocytosis Mast Cell Eosinophil
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.64 |
| 52 Week Low | 0.9799 |
| Average Volume | 491,744 |
| 200-Day Moving Average | 2.07 |
| 50-Day Moving Average | 1.20 |
| 20-Day Moving Average | 1.13 |
| 10-Day Moving Average | 1.20 |
| Average True Range | 0.09 |
| RSI (14) | 51.22 |
| ADX | 20.42 |
| +DI | 18.20 |
| -DI | 12.39 |
| Chandelier Exit (Long, 3 ATRs) | 1.03 |
| Chandelier Exit (Short, 3 ATRs) | 1.25 |
| Upper Bollinger Bands | 1.30 |
| Lower Bollinger Band | 0.96 |
| Percent B (%b) | 0.67 |
| BandWidth | 29.69 |
| MACD Line | 0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0167 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.28 | ||||
| Resistance 3 (R3) | 1.28 | 1.26 | 1.26 | ||
| Resistance 2 (R2) | 1.26 | 1.23 | 1.25 | 1.25 | |
| Resistance 1 (R1) | 1.22 | 1.22 | 1.21 | 1.22 | 1.25 |
| Pivot Point | 1.20 | 1.20 | 1.19 | 1.19 | 1.20 |
| Support 1 (S1) | 1.16 | 1.17 | 1.15 | 1.16 | 1.12 |
| Support 2 (S2) | 1.14 | 1.16 | 1.13 | 1.12 | |
| Support 3 (S3) | 1.10 | 1.14 | 1.11 | ||
| Support 4 (S4) | 1.10 |
